Employees: 602
Size OrthoPediatrics (KIDS) is a United States Health Care company (Medical Specialties) with a market value of $826M, the 2348th largest of 3,085 United States companies the cockpit tracks. Shares closed at $31.65 on 18 Nov 2026.
Performance Over six months the shares gained 71.1%, against -15.1% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 16.1% over the last twelve months (peer median +5.8%); the operating margin is -8.2% (peer median 10.2%).
Valuation It trades at 3.4× enterprise value to sales against a peer median of 3.6× (10th cheapest of 21).
Capital Return on invested capital runs 13.4 points below its cost of capital (9.1% WACC).
Short interest Short interest is 2.9% of the free float (30 Oct 2026).
Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $264M | $236M | $205M | $149M | $122M |
| Revenue growth | — | +15% | +38% | +22% | — |
| Gross profit | $172M | $152M | $130M | $93.9M | $77.6M |
| EBITDA | $1.26M | -$8.81M | -$10.8M | -$8.38M | -$8.31M |
| Net income | -$33.9M | -$39.6M | -$37.8M | -$21.0M | $1.24M |
| Free cash flow | $2.89M | -$16.0M | -$41.3M | -$43.9M | -$31.8M |
| Capital expenditure | $11.3M | $13.1M | $14.9M | $19.0M | $10.0M |
| Total debt | $106M | $117M | $84.7M | $23.8M | $16.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | KIDS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +34.7% | -5.1% | highest of 21 |
| 6-month return | +71.1% | -15.1% | 2nd highest of 21 |
| Distance from 52-week high | -8.3% | -40.3% | 4th highest of 21 |
| Revenue growth (TTM) | +16.1% | +5.8% | 6th highest of 21 |
| Operating margin | -8.2% | 10.2% | 5th lowest of 21 |
| EV / Sales | 3.4× | 3.6× | 10th cheapest of 21 |
| ROIC minus cost of capital | -13.4 pp | -1.6 pp | 5th lowest of 21 |
| Net debt / EBITDA | 48.5× | 0.1× | most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| OrthoPediatrics KIDS | United States | $826M | +71% | +16% | -8% | 3.4× | n/a | n/a |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $818M | -36% | +36% | 16% | 6.8× | 35.6% | +17.1% |
| Cofoe Medical Technology 1187.HK | Hong Kong | $836M | -11% | +40% | 10% | 1.0× | -6.4% | +6.6% |
| Beijing Hotgen Biotech 688068.SS | China | $815M | -37% | +8% | -94% | 9.6× | n/a | n/a |
| MedCap MCAP.ST | Sweden | $811M | -4% | +17% | 15% | 3.6× | 2.7% | +20.9% |
| Advanced Medical Solutions AMS.L | United Kingdom | $811M | +27% | +6% | 12% | 3.0× | 20.0% | +21.4% |
| Cisen Pharmaceutical 603367.SS | China | $843M | -15% | -6% | 8% | 0.7× | -14.6% | -1.3% |
| Modern Dental 3600.HK | Hong Kong | $844M | +24% | +12% | 22% | 1.6× | -7.1% | +11.3% |
| Seegene 096530.KS | South Korea | $808M | -26% | +13% | 13% | 1.2× | -6.7% | -15.9% |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $858M | -25% | +4% | 30% | 12.0× | 11.1% | +4.6% |
| HOB Biotech 688656.SS | China | $858M | -33% | +6% | 7% | 13.7× | 37.6% | +12.4% |
| Beijing SDL Technology 002658.SZ | China | $864M | -34% | -13% | 9% | 3.3× | 16.8% | +2.9% |
| Tinavi Medical Technologies 688277.SS | China | $872M | -36% | -2% | -59% | 21.7× | n/a | n/a |
| Standard Engineering Technology SETL.NS | India | $783M | +168% | +45% | 14% | 7.7× | n/a | n/a |
| Beta Bionics BBNX | United States | $779M | +42% | +44% | -73% | 4.3× | n/a | n/a |
| Xiangyu Medical 688626.SS | China | $877M | -38% | 0% | 4% | 7.2× | n/a | n/a |
| Hangzhou Biotest Biotech 688767.SS | China | $878M | -12% | -4% | 3% | 10.4× | n/a | n/a |
| Mesa Laboratories MLAB | United States | $775M | +33% | +2% | 10% | 3.6× | 21.3% | +13.2% |
| Shenzhen YHLO Biotech 688575.SS | China | $882M | -16% | +3% | 12% | 3.1× | 2.0% | +12.7% |
| Cytek Biosciences CTKB | United States | $774M | +57% | +6% | -21% | 2.6× | n/a | n/a |
| LifeTech Scientific 1302.HK | Hong Kong | $771M | -30% | +1% | 12% | 3.2× | 9.6% | +15.5% |